HCW Biologics Inc. has announced a significant amendment to its Equity Purchase Agreement with Square Gate Capital Master Fund, LLC-Series 4. Under the terms of this First Amendment, the company can now execute multiple purchases and sales of its common stock on the same trading day, enhancing its flexibility in capital management. The purchase price for these intraday transactions will be determined by the lowest traded price within a specified shortened valuation period. This enhanced agreement allows HCW Biologics to potentially raise up to $20 million over the next 36 months, providing a strategic financial resource to support its business operations and growth initiatives.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-109139), on August 15, 2025, and is solely responsible for the information contained therein.